Definium Therapeutics (DFTX) Non-Current Debt (2023 - 2026)

Definium Therapeutics (DFTX) has 4 years of Non-Current Debt data on file, last reported at $40.8 million in Q1 2026.

• On a quarterly basis, Non-Current Debt rose 85.03% year-over-year to $40.8 million in Q1 2026; TTM through Mar 2026 was $40.8 million, a 85.03% increase from a year earlier, with the FY2025 full-year figure at $40.6 million, up 85.68% from the prior year.
• Non-Current Debt for Q1 2026 stood at $40.8 million, roughly flat from $40.6 million in the prior quarter.
• Over the last five years, Non-Current Debt for DFTX reached as high as $41.2 million in Q2 2025 and fell as low as $14.1 million in Q3 2023.
• Historically, Non-Current Debt has averaged $27.1 million across 4 years, with a median of $24.3 million in 2024.
• Across the five-year window, Non-Current Debt surged 54.67% in 2024 and jumped 85.68% in 2025, its largest moves.
• Year by year, Non-Current Debt stood at $14.1 million in 2023, then jumped by 54.67% to $21.9 million in 2024, then soared by 85.68% to $40.6 million in 2025, then advanced by 0.48% to $40.8 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $40.8 million in Q1 2026, $40.6 million in Q4 2025, and $40.4 million in Q3 2025.